<DOC>
	<DOCNO>NCT00093665</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , fluorouracil cisplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining fluorouracil cisplatin radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give fluorouracil cisplatin together radiation therapy work treat patient stage II , stage III , stage IV nasopharyngeal cancer .</brief_summary>
	<brief_title>Fluorouracil , Cisplatin , Radiation Therapy Treating Patients With Stage II , Stage III , Stage IV Nasopharyngeal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine progression-free survival patient previously untreated stage IIB-IVB nasopharyngeal cancer treat fluorouracil , cisplatin , radiotherapy . Secondary - Determine overall survival response rate patient treat regimen . - Determine compliance regimen patient . - Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients receive chemotherapy comprise fluorouracil IV continuously day 1-5 cisplatin IV continuously day 6-7 . Beginning 2-3 day completion chemotherapy , patient undergo radiotherapy daily , 5 day week , 4 week . With 2-3 day course , patient receive second course chemotherapy , undergo second course radiotherapy , receive third course chemotherapy . Treatment continue absence unacceptable toxicity disease progression . Patients follow 3 year . PROJECTED ACCRUAL : A total 90 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Nasopharyngeal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm nasopharyngeal cancer ( NPC ) Type IIII disease WHO classification Stage IIBIVB disease TNM classification distant metastases chest xray , liver ultrasonography CT scan , bone scintigraphy Lymph node metastasis evaluate CT scan , MRI , palpation Progression range primary lesion evaluate MRI pharyngeal fiberoptic endoscopy PATIENT CHARACTERISTICS : Age 18 70 Performance status ECOG 02 Life expectancy Not specify Hematopoietic WBC &gt; 3,500/mm^3 Platelet count &gt; 100,000/mm^3 Hepatic No severe hepatic dysfunction Renal Creatinine clearance &gt; 60 mL/min No severe renal dysfunction Cardiovascular No severe cardiac dysfunction Pulmonary No severe pulmonary dysfunction Other No active cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior biologic therapy NPC Chemotherapy No prior systemic chemotherapy NPC Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2006</verification_date>
	<keyword>stage II lymphoepithelioma nasopharynx</keyword>
	<keyword>stage III lymphoepithelioma nasopharynx</keyword>
	<keyword>stage IV lymphoepithelioma nasopharynx</keyword>
	<keyword>stage II squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
</DOC>